Mainz Biomed Statistics
Total Valuation
Mainz Biomed has a market cap or net worth of $7.72 million. The enterprise value is $4.75 million.
Important Dates
The next estimated earnings date is Tuesday, May 20, 2025, before market open.
| Earnings Date | May 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mainz Biomed has 3.04 million shares outstanding. The number of shares has increased by 138.45% in one year.
| Current Share Class | 3.04M |
| Shares Outstanding | 3.04M |
| Shares Change (YoY) | +138.45% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.69% |
| Owned by Institutions (%) | 1.55% |
| Float | 2.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.75 |
| Forward PS | 5.04 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 2.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.54.
| Current Ratio | 1.32 |
| Quick Ratio | 1.08 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.13 |
Financial Efficiency
Return on equity (ROE) is -465.82% and return on invested capital (ROIC) is -115.18%.
| Return on Equity (ROE) | -465.82% |
| Return on Assets (ROA) | -80.37% |
| Return on Invested Capital (ROIC) | -115.18% |
| Return on Capital Employed (ROCE) | -252.70% |
| Revenue Per Employee | $34,384 |
| Profits Per Employee | -$832,718 |
| Employee Count | 26 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.38% in the last 52 weeks. The beta is 0.51, so Mainz Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -90.38% |
| 50-Day Moving Average | 3.72 |
| 200-Day Moving Average | 7.91 |
| Relative Strength Index (RSI) | 35.65 |
| Average Volume (20 Days) | 302,340 |
Short Selling Information
The latest short interest is 155,350, so 5.11% of the outstanding shares have been sold short.
| Short Interest | 155,350 |
| Short Previous Month | 69,425 |
| Short % of Shares Out | 5.11% |
| Short % of Float | 5.64% |
| Short Ratio (days to cover) | 0.53 |
Income Statement
In the last 12 months, Mainz Biomed had revenue of $893,991 and -$21.65 million in losses. Loss per share was -$22.36.
| Revenue | 893,991 |
| Gross Profit | 574,883 |
| Operating Income | -18.42M |
| Pretax Income | -26.30M |
| Net Income | -21.65M |
| EBITDA | -17.71M |
| EBIT | -18.42M |
| Loss Per Share | -$22.36 |
Full Income StatementBalance Sheet
The company has $6.24 million in cash and $3.27 million in debt, giving a net cash position of $2.96 million or $0.98 per share.
| Cash & Cash Equivalents | 6.24M |
| Total Debt | 3.27M |
| Net Cash | 2.96M |
| Net Cash Per Share | $0.98 |
| Equity (Book Value) | 6.05M |
| Book Value Per Share | 2.61 |
| Working Capital | 1.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.09 million and capital expenditures -$104,949, giving a free cash flow of -$17.19 million.
| Operating Cash Flow | -17.09M |
| Capital Expenditures | -104,949 |
| Free Cash Flow | -17.19M |
| FCF Per Share | -$5.66 |
Full Cash Flow StatementMargins
| Gross Margin | 64.31% |
| Operating Margin | -2,060.23% |
| Pretax Margin | -2,421.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mainz Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -138.45% |
| Shareholder Yield | -138.45% |
| Earnings Yield | -280.50% |
| FCF Yield | -222.77% |
Analyst Forecast
The average price target for Mainz Biomed is $14.00, which is 451.18% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.00 |
| Price Target Difference | 451.18% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 143.03% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 3, 2024. It was a reverse split with a ratio of 0.025:1.
| Last Split Date | Dec 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.025:1 |
Scores
Mainz Biomed has an Altman Z-Score of -12.85 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.85 |
| Piotroski F-Score | 4 |